Mereo BioPharma(MREO)

Search documents
Mereo BioPharma(MREO) - 2022 Q4 - Annual Report
2023-03-28 20:37
Exhibit 99.1 Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights — London, March 28, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. "In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ...
Mereo BioPharma(MREO) - 2022 Q2 - Quarterly Report
2022-11-02 20:17
Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income (unaudited) | | | Six months | Six months | | --- | --- | --- | --- | | | | ended June 30, | ended June 30, | | | | 2022 | 2021 | | | Notes | £'000 | £'000 | | Revenue | 3 | — | 36,464 | | Cost of revenue | 3 | 352 | (18,137) | | Research and development expenses | | (13,322) | (9,858) | | Administrative expenses | | (8,840) | (8,673) | | Operating loss | | (21,810) | (204) | | Finance income | 4 | 173 | ...
Mereo BioPharma(MREO) - 2021 Q4 - Annual Report
2022-03-31 20:19
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...
Mereo BioPharma (MREO) Investor Presentation - Slideshow
2021-09-26 16:29
| --- | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | Unlocking the potential of novel targets for cancer and rare diseases | | | | M e r e o B i o P h a r m a G r o u p p l c N A S D A Q : M R E O | S e p t e m b e r 2 0 2 1 | | | Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information an ...
Mereo BioPharma(MREO) - 2020 Q4 - Annual Report
2021-03-31 20:53
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . FORM 20-F (Mark One) ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...
Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call (Transcript)
2020-09-29 14:11
Mereo BioPharma Group plc (NASDAQ:MREO) 2020 Interim Financial Results Conference Call September 29, 2020 8:00 AM ET Company Participants Steve Klass - IR, Burns McClellan Denise Scots-Knight - CEO Michael Wyzga - Interim CFO John Lewicki - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2020 Interim Results Conference Call. At this time, all participants are in a list ...
Mereo BioPharma(MREO) - 2019 Q4 - Annual Report
2020-06-15 20:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...
Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2019 Interim Financial Results and Corporate Update Conference Call
2019-09-17 18:09
Mereo BioPharma Group plc (NASDAQ:MREO) 2019 Interim Financial Results and Corporate Update Conference Call September 17, 2019 8:00 AM ET Company Participants Richard Jones – Chief Financial Officer Denise Scots-Knight – Chief Executive Officer Conference Call Participants Brian White – Cantor Fitzgerald Zoe Karamanoli – RBC Capital Markets Mick Cooper – Trinity Delta Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2019 Interim Results Conference Call ...
Mereo BioPharma(MREO) - 2019 Q2 - Earnings Call Presentation
2019-09-17 13:49
| --- | --- | --- | --- | |-------|-------------------------|-------|-------| | | | | | | | | | | | | 2019 INTERIMS CORPORATE | | | DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for use at a presentation for th ...
Mereo BioPharma(MREO) - 2018 Q4 - Annual Report
2019-04-29 20:59
OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the fiscal year ended December 31, 2018 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...